文献速递烧伤创面修复

菠萝蛋白酶酶性清创与标准治疗在深度烧伤中的比较:系统综述与Meta分析

Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Burn Care Res · 2025-01-01

本系统综述与Meta分析检索Cochrane Library、Embase和Medline至2024年5月30日,纳入7项研究共484例患者,其中238例(49%)接受酶性清创。菠萝蛋白酶酶性清创较标准治疗显著缩短焦痂清除时间(MD -7.60天,95%CI [-9.76, -5.44];I²=70%),并显著降低手术切除风险(RR 0.17;95%CI [0.06, 0.47];I²=79%)和自体移植需求(RR 0.40;95%CI [0.18, 0.93];I²=76%),创面闭合时间与改良温哥华瘢痕量表评分无显著差异。

要点

  • 菠萝蛋白酶酶性清创较标准治疗显著缩短焦痂清除时间,MD -7.60天(95%CI [-9.76, -5.44])。
  • 菠萝蛋白酶组手术切除风险显著低于标准治疗组,RR 0.17(95%CI [0.06, 0.47])。
  • 菠萝蛋白酶组自体移植需求显著低于标准治疗组,RR 0.40(95%CI [0.18, 0.93])。

核心结论

  • 菠萝蛋白酶酶性清创可能加速焦痂清除并减少手术切除和自体移植需求,且未对创面闭合时间或长期瘢痕质量产生不良影响。

研究设计与样本

  • 系统综述与Meta分析,检索Cochrane Library、Embase和Medline至2024年5月30日,纳入7项比较菠萝蛋白酶酶性清创与标准治疗的研究,共484例患者,其中238例(49%)接受酶性清创。

主要发现

  • 菠萝蛋白酶组较标准治疗组显著缩短焦痂清除时间,MD -7.60天(95%CI [-9.76, -5.44];I²=70%)。
  • 菠萝蛋白酶组较标准治疗组显著降低手术切除风险,RR 0.17(95%CI [0.06, 0.47];I²=79%)。
  • 菠萝蛋白酶组较标准治疗组显著降低自体移植需求,RR 0.40(95%CI [0.18, 0.93];I²=76%)。
  • 两组创面闭合时间无显著差异,MD -7.64天(95%CI [-18.46, 3.18];I²=86%)。
  • 两组改良温哥华瘢痕量表评分无显著差异,MD -0.36分(95%CI [-0.96, 0.23];I²=0%)。

临床怎么用

  • 作者认为,菠萝蛋白酶酶性清创可能加速焦痂清除并减少手术切除和自体移植需求,且未对创面闭合时间或长期瘢痕质量产生不良影响。

局限性

  • 焦痂清除时间分析存在异质性,I²=70%。
  • 手术切除风险分析存在异质性,I²=79%。
  • 自体移植需求分析存在异质性,I²=76%。
  • 创面闭合时间分析存在异质性,I²=86%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deep burn injuries necessitate effective debridement to promote healing and reduce complications. Traditional surgical debridement is the standard of care; however, it can lead to significant tissue loss, excessive bleeding and delayed healing. Bromelain-based enzymatic debridement offers a potential less invasive alternative that aims to selectively remove necrotic tissue while preserving viable ones. Therefore, this systematic review and meta-analysis comprehensively compares bromelain debridement versus standard care in the management of partial and full thickness burns. Cochrane Library, Embase, and Medline were searched until May 30, 2024 for studies comparing bromelain debridement versus standard care. R version 4.4.0 was used to pooled risk ratio and mean difference in a random-effects model. We included 7 studies, comprising 484 participants, of whom 238 (49%) were treated with enzymatic debridement. Bromelain significantly reduced time to eschar removal (MD -7.60 days 95% CI [-9.76, -5.44]; I2 = 70%) in comparison with standard care. Additionally, bromelain group presented a significant reduction in the risk of surgical excision (RR 0.17; 95% CI [0.06, 0.47]; I2 = 79%) and need for autografts (RR 0.40; 95% CI [0.18, 0.93]; I2 = 76%) in comparison with standard group. No differences were found in behalf of time to wound closure (MD -7.64 days; 95% CI [-18.46]-[3.18]; I2 = 86%), nor in Modified Vancouver Scar Scale (MD -0.36 points; 95% CI [-0.96]-[0.23]; I2 = 0%). Bromelain-based enzymatic debridement may accelerate eschar removal and reduce the need for surgical excision and autografts, without adversely affecting wound closure time or long-term scar quality.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. De Freitas LR, Udoma-Udofa OC, Reginato PH, et al. Bromelain-Based Enzymatic Debridement Versus Standard of Care in Deep Burn Injuries: A Systematic Review and Meta-Analysis. J Burn Care Res. 2025. PMID: 39259807. doi:10.1093/jbcr/irae172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。